Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Apr;77(7):1072–1081. doi: 10.1038/bjc.1998.179

Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.

K F Yoong 1, D H Adams 1
PMCID: PMC2150140  PMID: 9569042

Abstract

Metastatic colorectal cancer is usually progressive despite infiltration of the tumours by T lymphocytes, suggesting that these tumour-infiltrating lymphocytes (TILs) are functionally deficient. Recently, TILs from other tumours have been shown to express reduced levels of the T-cell receptor signal-transducing CD3-zeta chain. We were interested to determine whether a similar abnormality existed in TILs from human colorectal hepatic metastasis (CHM) and, if so, whether correcting the abnormality in vitro would restore anti-tumour activity and provide support for the development of immunotherapy for colorectal hepatic metastases. Twelve of 19 TILs from colorectal hepatic metastases were successfully expanded in vitro in high-dose recombinant interleukin 2 (rlL-2) and their specific anti-tumour cytolytic activity was determined. CD3-positive (CD3+) TILs were HLA-Drhigh and CD69high, suggesting that they had been activated by exposure to antigen but expressed low levels of CD25, CD71 and the nuclear proliferation antigen Ki-67. Furthermore, they showed reduced expression of CD3-zeta compared with autologous peripheral blood T cells (PBTs) and failed to proliferate in the absence of high-dose rIL-2. Expansion of TILs in rIL-2 resulted in restoration of CD3-zeta expression and the ability to lyse K562 and Daudi cells but not autologous tumour cells. The absence of autologous tumour-specific cytolytic T-cell (CTL) activity may be due to the poor immunogenicity of colorectal tumour cells, which we found expressed only low levels of MHC I antigens and CD54 and failed to express MHC II antigens or the co-stimulatory molecules CD80, CD86 or CD106. The inability of rIL-2 to generate tumour-specific CTLs despite restoration of CD3-zeta expression and the presence of an intact lytic mechanism suggests that successful immunotherapy may require the development of strategies to increase the immunogenicity of this tumour.

Full text

PDF
1072

Images in this article

1075Figure 1
on p.1075

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Hubscher S. G., Fisher N. C., Williams A., Robinson M. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology. 1996 Sep;24(3):533–538. doi: 10.1002/hep.510240311. [DOI] [PubMed] [Google Scholar]
  2. Adams D. H., Yannelli J. R., Newman W., Lawley T., Ades E., Rosenberg S. A., Shaw S. Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br J Cancer. 1997;75(10):1421–1431. doi: 10.1038/bjc.1997.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Allison J. P., Hurwitz A. A., Leach D. R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct;7(5):682–686. doi: 10.1016/0952-7915(95)80077-8. [DOI] [PubMed] [Google Scholar]
  4. Asbun H. J., Hughes K. S. Management of recurrent and metastatic colorectal carcinoma. Surg Clin North Am. 1993 Feb;73(1):145–166. doi: 10.1016/s0039-6109(16)45934-7. [DOI] [PubMed] [Google Scholar]
  5. Baer H. U., Gertsch P., Matthews J. B., Schweizer W., Triller J., Zimmermann A., Blumgart L. H. Resectability of large focal liver lesions. Br J Surg. 1989 Oct;76(10):1042–1044. doi: 10.1002/bjs.1800761019. [DOI] [PubMed] [Google Scholar]
  6. Barth R. J., Jr, Camp B. J., Martuscello T. A., Dain B. J., Memoli V. A. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer. 1996 Sep 15;78(6):1168–1178. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1168::AID-CNCR2>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  7. Bateman W. J., Donnellan I., Fraser I. A., Wong L. S., Morris A. G. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma. Cancer Immunol Immunother. 1995 Jul;41(1):61–67. doi: 10.1007/BF01788961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boussiotis V. A., Gribben J. G., Freeman G. J., Nadler L. M. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994 Oct;6(5):797–807. doi: 10.1016/0952-7915(94)90087-6. [DOI] [PubMed] [Google Scholar]
  9. Burno D. K., Fabian D. F., Lefor A. T. ICAM-1 increases in vitro adhesion and cytotoxicity in a murine fibrosarcoma. J Surg Res. 1996 Feb 1;60(2):398–402. doi: 10.1006/jsre.1996.0065. [DOI] [PubMed] [Google Scholar]
  10. Burno D. K., Kyprianou N., Sartor W. M., Fabian D. F., Turner J., Vu T., Patel A., Trimbach C., Lefor A. T. Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery. 1995 Aug;118(2):237–244. doi: 10.1016/s0039-6060(05)80329-0. [DOI] [PubMed] [Google Scholar]
  11. Camp B. J., Dyhrman S. T., Memoli V. A., Mott L. A., Barth R. J., Jr In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol. 1996 Mar;3(2):176–184. doi: 10.1007/BF02305798. [DOI] [PubMed] [Google Scholar]
  12. Campana D., Coustan-Smith E., Janossy G. Double and triple staining methods for studying the proliferative activity of human B and T lymphoid cells. J Immunol Methods. 1988 Feb 24;107(1):79–88. doi: 10.1016/0022-1759(88)90012-9. [DOI] [PubMed] [Google Scholar]
  13. Cavallo F., Martin-Fontecha A., Bellone M., Heltai S., Gatti E., Tornaghi P., Freschi M., Forni G., Dellabona P., Casorati G. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol. 1995 May;25(5):1154–1162. doi: 10.1002/eji.1830250504. [DOI] [PubMed] [Google Scholar]
  14. Chambers C. A., Allison J. P. Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun;9(3):396–404. doi: 10.1016/s0952-7915(97)80087-8. [DOI] [PubMed] [Google Scholar]
  15. Coventry B. J., Weeks S. C., Heckford S. E., Sykes P. J., Bradley J., Skinner J. M. Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J Immunol. 1996 May 1;156(9):3486–3492. [PubMed] [Google Scholar]
  16. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O'Shea J. J., Kudoh S., Klein E. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993 Dec 1;53(23):5613–5616. [PubMed] [Google Scholar]
  17. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458–6462. doi: 10.1073/pnas.91.14.6458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kudoh S., Stanley J., Edinger M. G., Tubbs R. R., Klein E., Bukowski R. M., Finke J. H. T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. Int J Cancer. 1994 Aug 1;58(3):369–375. doi: 10.1002/ijc.2910580311. [DOI] [PubMed] [Google Scholar]
  19. Lanier L. L., Phillips J. H. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today. 1996 Feb;17(2):86–91. doi: 10.1016/0167-5699(96)80585-8. [DOI] [PubMed] [Google Scholar]
  20. Maeurer M. J., Martin D. M., Castelli C., Elder E., Leder G., Storkus W. J., Lotze M. T. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1995 Aug;41(2):111–121. doi: 10.1007/BF01527407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer. 1988 Nov 15;42(5):659–666. doi: 10.1002/ijc.2910420504. [DOI] [PubMed] [Google Scholar]
  22. Miescher S., Whiteside T. L., Carrel S., von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986 Mar 1;136(5):1899–1907. [PubMed] [Google Scholar]
  23. Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992 Dec 11;258(5089):1795–1798. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  24. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J. L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993 Dec 1;53(23):5610–5612. [PubMed] [Google Scholar]
  25. Nakagomi H., Pisa P., Pisa E. K., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer. 1995 Nov 3;63(3):366–371. doi: 10.1002/ijc.2910630311. [DOI] [PubMed] [Google Scholar]
  26. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996 Sep 1;184(3):1075–1082. doi: 10.1084/jem.184.3.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases. Surgery. 1988 Mar;103(3):278–288. [PMC free article] [PubMed] [Google Scholar]
  28. Rivoltini L., Kawakami Y., Sakaguchi K., Southwood S., Sette A., Robbins P. F., Marincola F. M., Salgaller M. L., Yannelli J. R., Appella E. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol. 1995 Mar 1;154(5):2257–2265. [PubMed] [Google Scholar]
  29. Robbins P. F., Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 1996 Oct;8(5):628–636. doi: 10.1016/s0952-7915(96)80078-1. [DOI] [PubMed] [Google Scholar]
  30. Robey E., Allison J. P. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 1995 Jul;16(7):306–310. doi: 10.1016/0167-5699(95)80140-5. [DOI] [PubMed] [Google Scholar]
  31. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994 Aug 3;86(15):1159–1166. doi: 10.1093/jnci/86.15.1159. [DOI] [PubMed] [Google Scholar]
  32. Sanderson C. J. The uptake and retention of chromium by cells. Transplantation. 1976 Jun;21(6):526–529. [PubMed] [Google Scholar]
  33. Sayegh M. H., Akalin E., Hancock W. W., Russell M. E., Carpenter C. B., Linsley P. S., Turka L. A. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 1995 May 1;181(5):1869–1874. doi: 10.1084/jem.181.5.1869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schendel D. J., Gansbacher B., Oberneder R., Kriegmair M., Hofstetter A., Riethmüller G., Segurado O. G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol. 1993 Oct 15;151(8):4209–4220. [PubMed] [Google Scholar]
  35. Schwartz R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992 Dec 24;71(7):1065–1068. doi: 10.1016/s0092-8674(05)80055-8. [DOI] [PubMed] [Google Scholar]
  36. Shimizu Y., Iwatsuki S., Herberman R. B., Whiteside T. L. Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. Int J Cancer. 1990 Nov 15;46(5):878–883. doi: 10.1002/ijc.2910460521. [DOI] [PubMed] [Google Scholar]
  37. Townsend S. E., Allison J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993 Jan 15;259(5093):368–370. doi: 10.1126/science.7678351. [DOI] [PubMed] [Google Scholar]
  38. Townsend S. E., Su F. W., Atherton J. M., Allison J. P. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994 Dec 15;54(24):6477–6483. [PubMed] [Google Scholar]
  39. Yannelli J. R. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. J Immunol Methods. 1991 May 17;139(1):1–16. doi: 10.1016/0022-1759(91)90345-g. [DOI] [PubMed] [Google Scholar]
  40. Yoong K. F., Adams D. H. Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications. Clin Mol Pathol. 1996 Oct;49(5):M256–M267. doi: 10.1136/mp.49.5.m256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES